The predictions from our network pharmacology analysis were validated by our in vivo findings: the SCF treatment effectively decreased both lipid peroxide and pro-inflammatory cytokines in the hippocampus of Aβ (25-35)-infused rats and notably reduced AChE activity in the AD-SCF group [24]. This evidence concerns the gene KITLG and Alzheimer disease.